ASCO 2021: MonarchE Subanalysis Showed Benefits of Abemaciclib Extend to Patients With High-Risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy
Benefits were similar to those observed in the overall intent-to-treat population
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.